Background and aims. Entecavir (ETV) is effective and safe in patients with chronic hepatitis
B in the short term, but its long term efficacy and safety has not been established. Material …

Introduction: Registration studies showed entecavir (ETV) to be effective and safe in NUC‐
naïve patients with chronic hepatitis B virus (HBV), but its effectiveness in routine clinical …

Sustained virologic suppression is a primary goal of therapy for chronic hepatitis B (CHB). In
study entecavir (ETV)‐022, 48 weeks of entecavir 0.5 mg was superior to lamivudine for …

OBJECTIVES: We aimed to determine the antiviral potency, viral resistance rate, and clinical
safety of 3-year continuous entecavir treatment. METHODS: We determined the cumulative …

Abstract Background and Aim Although entecavir has been shown to have good efficacy
and low resistance for the treatment of chronic hepatitis B (CHB), factors associated with a …

Background: Entecavir (ETV) has been shown to be effective in randomized controlled trials
in highly selected patients with hepatitis B virus (HBV) infection. This study aimed to …

BACKGROUND & AIMS: To evaluate the long-term efficacy of entecavir in nucleoside-naïve
chronic hepatitis B patients. METHODS: One hundred and sixty-seven patients treated with …

Background Entecavir is an effective treatment for chronic hepatitis B. However, data from
clinical practice are limited, especially in hepatitis B e antigen (HBeAg)-positive patients …

Materials and methods This study was based on a large real-life cohort of 2240 chronic
hepatitis B patients treated with ETV between January 2006 and December 2012 using a …

Objective As the efficacy of a direct antiviral agent is reduced in cirrhotic chronic hepatitis C
patients, prolonged duration of treatment or addition of ribavirin is recommended to improve …